Equibles does not estimate personal net worth.
Get an email with a short summary when BridgeBio Pharma, Inc. publishes a filing, an earnings call transcript or a press release.
Get BBIO alertsMatt Outten is recorded as CFO at BridgeBio Pharma, Inc. (BBIO). Matt Outten has spoken on 5 earnings calls and 1 other investor event across 1 company, most recently for BridgeBio Pharma, Inc. on October 29, 2026. BridgeBio Pharma, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at BridgeBio Pharma, Inc. includes Neil Kumar (CEO and Board Member), Charles Homcy (Chairman and Board Member), Brian Stephenson (CFO) and 7 others.
“This is an exciting and pivotal moment for BridgeBio. Atrube is continuing its growth trajectory. The PDUFA date for infagradinib has been assigned as February 4th.”
“Now, Q2 was another strong quarter that demonstrated consistent growth in the treatment-naive segment for a TRUBI, as physicians are increasingly starting and keeping patients on a TRUBI.”
“Q1 was another strong quarter for a Truby, delivering an impressive 24% increase in net sales from Q4 and a 392% year-over-year increase from Q1 2025. Growth was driven by our existing and expanded sales teams, accelerating new patient starts and first-line share gains.”
“I would just say that we'll get more specific in terms of data and evidence that we're generating. Our medical team has got a very broad evidence generation plan that they're executing on.”
“I'm pleased to report that Atruvi has achieved exceptional performance in the second quarter of 2025, generating $71.5 million in net product revenue, representing 100% growth over quarter one, essentially a doubling of net product revenue.”
Biotechnology · Healthcare
CFO
